In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Motorola a Match for Incyte Content

Executive Summary

Incyte Genomics licensed its portfolio of proprietary gene sequences to Motorola's BioChip Systems division, which will use the information to make bioarrays for gene expression, SNP scoring, genotyping, and protein expression. In addition, Motorola software will enable users to click through to Incyte's Web site for the purchase of additional gene sequence information and reagents, a much-needed boost to Incyte's attempts to direct researchers to its Web-based genomics database.

You may also be interested in...



There’s No Need To Include Off-Label Use In Labeling, FDA Says In Proposed Rule

After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.

Legal Experts Predict How US Supreme Court Shake-Up Will Impact Medtech

If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.

Salvia Scores $31M To Develop Neurostimulation Therapy

The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.

Topics

Related Companies

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel